Quantcast

Latest CD4 Stories

2011-09-27 12:02:51

One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment. Some recent studies have found that starting highly active antiretroviral therapy earlier is better. Now a new study led by researchers at the University of North Carolina at Chapel Hill finds that there may be a limit to how early the therapy, known as HAART, should start. The new results could help determine where the starting line for antiretroviral therapy should...

2011-08-20 07:00:00

SeraCare announced the addition of Cryo-M Human Monocytes and Cryo-T4 Human CD4+ T-Cells to its AccuCell® Peripheral Blood Mononuclear Cell (PBMC) portfolio. Milford, MA (PRWEB) August 20, 2011 SeraCare Life Sciences, a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced it has expanded its cellular product line with the addition of Cryo-M Human Monocytes and Cryo-T4...

2011-07-20 12:19:43

In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return for the results of their initial CD4 count (a prognostic and treatment eligibility biomarker); some disappear between having their initial CD4 count taken and becoming eligible for HIV treatment; and others with CD4 counts that indicate that they are eligible for...

2011-07-11 08:00:00

WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. AE37, an Ii-Key HER-2 hybrid, is currently the subject of a...

2011-06-15 21:17:50

Specific types of "helper" T cells that are crucial to maintaining functioning immune systems contain an enzyme called PDI (protein disulfide isomerase). This enzyme affects how proteins fold into specific shapes, which in turn influences how the T cells behave. PDI also plays a role in HIV infection by helping to change the shape of the surface envelope protein of the virus, enabling the virus to interact optimally with receptors on the T cells, such as the CD4 molecule. Though it is known...

2011-05-16 19:16:07

Mouse studies point to long-lasting protection against HIV infection using topical, RNAi-based microbicide Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission. The microbicide is predicted to have long-lasting effects in mice, opening the door to developing an intravaginal microbicide that could protect women against HIV infection potentially for weeks at a time and...

2011-05-16 18:19:15

The HIV epidemic is continuing spread and efforts to develop a vaccine that protects against infection are still showing limited promise. Therefore, researchers are seeking to develop alternative approaches to block HIV transmission. One such strategy is vaginal application of an agent known as a microbicide, which works to kill the virus at the site of entry into the body. A team of researchers, led by Judy Lieberman, at Harvard Medical School, Boston, has now developed a new agent that they...

2011-04-04 08:00:00

WORCESTER, Mass. and TORONTO, April 4, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of a report comparing the clinical characteristics of three different immunotherapeutic peptide vaccines designed for immunotherapy of breast cancer. One of those, AE37, is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). (Logo:...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related